CapsoVision(NASDAQ) CV

CapsoVision, Inc. makes camera pills to see inside patients. Doctors use these to find diseases without using long tubes. The pill travels naturally while recording video of the body.

A Look Inside the Patient

• CapsoCam Plus: Capsule endoscopy system for imaging the small bowel in adults and children aged 2 years and above.
• CapsoCam Colon: Imaging device for detecting polyps and measuring their size in the large intestine.
• CapsoCloud: Cloud-based software that allows medical professionals to review patient videos remotely.
• CapsoView: Local data access software used for viewing capsule videos on a computer.
• CapsoRetrieve: Specialized retrieval kit that uses a magnetic wand to recover the capsule from the patient.

Trials and Strategic Moves

• Started a clinical study for early pancreatic cancer detection using the CapsoCam UGI system in May 2026.
• Submitted a regulatory application for a specialized bowel passage verification capsule in July 2026.
• Completed a private placement of stock that generated $13.4 million in net proceeds in March 2026.
• Shifted resources toward a second-generation colon capsule featuring improved imaging and artificial intelligence.

How the Technology Differs

CapsoVision uses 360-degree panoramic imaging to view the entire lining of the small bowel. This cloud-based approach allows clinicians to access patient data at any time without maintaining on-site servers.

Measuring Recent Financial Performance

• Revenue reached $6.4 million for the six-month period ended June 30, 2026, up 6% year over year.
• Net loss was $14.5 million for the six-month period ended June 30, 2026, up 45% year over year.
• Gross margin was 50% for the six-month period ended June 30, 2026, down from 54% in the prior year.
• Research and development expenses rose 50% to $9.7 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents totaled $9.1 million as of June 30, 2026.

Bottom Line

CapsoVision has evolved from a medical device startup into a public company focused on integrating artificial intelligence into gastrointestinal imaging. Its growth depends on obtaining regulatory clearances for new products and successfully expanding beyond small bowel diagnostics.